Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Aug 13, 2010 4:23pm
803 Views
Post# 17349829

Sprott endorses Quetzal once again

Sprott endorses Quetzal once againOn BNN today at 3.15, Peter Hodson, senior portfolio manager for Sprott Asset Management, talks about some small cap investments. He pans Quetzel and points out that 
  1)  QEI has an excellent management team
  2)  QEI has a newly drilled discovery well in an area adjacent to some other huge discoveries
  3)   We will soon know the daily flow rate of this new discovery made by Quetzel

Thus he reckons that QEI has become somewhat less risky as a potential investment. However he points out that investors are wise to wait a number of years to let management do their job and improve shareholder value

I am thinking that Mr. Hodson's comments were responsible for today's increase in trading volume and share price. Sprott is a highly respected wealth management firm. They have one of the best track records for investing in the very challenging small cap space.

And remember that in Columbia, the low hanging oil fruit has been taken. Now the deeper formations are being tested.  This requires 3-D seismic data, big rigs, and alot more time and money.  

Companies to the north , south and west  of QEI have made significant finds in this part of the Llanos basin. Now it is hopefully our turn. We shall see.
Bullboard Posts